The development of acute
stroke units in most
hospitals in the UK has been the major recent change in stroke care
that
benefits the majority of patients. The reasons for this are more
difficult to determine but is likely to be due to concentration of
skills, training & retention of staff with an interest in
stroke and
implementation of proven best practice.
They
certainly appear to improve outcome in comparison to a mobile stroke
team wandering the
medical wards or normal general medical ward care. In
hospitals with a small unit the patients likely to benefit the most are
those
with a stroke of moderate severity. All patients are likely
to benefit to some extent though so admission is encouraged for all
proven
strokes.
Ongoing
treatment of stroke
patients
Secondary PreventionPreventing
a further stroke is a prime concern and the risk of a further stroke is
highest soon after the initial event. Antiplatelets,
antihypertensives and statins are the mainstay of medical treatment.
Whilst lifestyle advice including stopping smoking, sensible
eating and an active lifestyle are the main non-pharmaceutical benefits.
Anti-plateletsThe
current advice from NICE is that all patients who suffer a TIA or a
stroke should be on aspirin and dipyridamole SR for a period of two
years before reverting to aspirin alone for life. If a
patient is genuinely aspirin intolerant than clopidogrel monotherapy is
recommended lifelong. Dipridamole SR alone is probably
inadequate but aspirin alone if a patient is intolerant of dipyridamole
SR is considered satisfactory. There is a suggestion that in
high risk patients (arteriopaths) clopidogrel may have a small but
significant advantage over aspirin.
Anti-hypertensivesChoice
of anti-hypertensives is probably not as critical as some people whould
have us believe. The important factor is blood pressure
control not strictly speaking how this is achieved. It is
likely that ACE inhibitors (such as ramipril) and thiazide diuretics
(such as bendroflumethiazide) have some small additional benefit in
stroke prevention on top of their anti-hypertensive effect and
therefore may be considered first line. Whatever works for
the individual patient is probably the best philosophy of course.
StatinsStatin
therapy again produces a small but significant reduction in recurrent
stroke (less impressive than its effect in cardiac disease but then
stroke is at least three different aetiologies). Because it
is likely to have little or minimal effect on haemmorhages and cardiac
embolic strokes any effect on atherosclerotic stroke is watered down.
It is reasonable to use the cheapest statin which has proven
to work in stroke at an effective dose so simvastation 40mg seems a
good choice though my personal practice is not to change from another
statin if the patient is already established on another type.
You
are probably more likely to prevent a MI than a stroke by using statins
in this way but that is of course no bad thing. The current
recommendations are that anyone with a random total cholesterol (within
48hrs of admission otherwise lack of nutrition may affect it) above 3.5
mmol/L should be considered for treatment so essentially everyone.
Other cholesterol lowering therapies (non-statins) do not
currently have moratlity or stroke prevention data and therefore are
difficult to recommend as first line.
Other
interventionsAnticoagulationsCan
only currently be recommended in patients with an ischaemic stroke with
atrial fibrillation or other cardiac source of emboli.
Warfarin has no proven role in patients in sinus rhythm with
multiple TIAs or strokes.
Carotid
surgeryIn patients who are both fit enough for
surgery and have made a good recovery from a carotid territiory TIA or
stroke should have a doppler assessment or other radiological
investigations of their carotids. General advice is that
there must be a 70-99% stenosis on the correct side for the stroke to
benefit sufficiently to warrant the risk of surgery. There
are other situations where surgery may be considered so speak to your
local vascular surgeons if uncertain.
Saline
bubble echocardiographyThe above investigation
is to look for a patent foramen ovale which can sometimes be
responsible for a stroke. However they are extrememly common
in normal indivduals (25% of us) and so should only be looked for in
patients with no risk factors for stroke who then unexpectedly have a
proven cerebral infarction. Best to discuss with your local
stroke physician and cardiologist before routinely requesting this
investigation.
Nutrition
/ Artificial FeedingNutrition in all patients
is an
important issue but is of course complicated in stroke medicine by the
impaired swallow and increased risk of aspiration in this patient
group. Despite this blanket NBM orders on all stroke patients
will deny many patients that are perfectly safe to swallow adequate
nutrition and fluids
The recommendations is that all
patients have a swallowing assessment early so that it can be
determined whether they need restrictions and referral to a trained
Speech and Language Therapist or whether they can be allowed to eat and
drink. Dysphagia screening test are quick to learn and can be performed
at the bedside by a suitable trained member of staff.
If
after 48 hours inadequate nutrition intake is occuring then it is
important to consider NG tube insertion in patients unless the
expectation is that they are deterioating rapidly. PEG
insertion has not shown to be advantageous over NG and carries its own
risks so is not uusally considered until three weeks has passed or
there are repeated NG failures and there is still no sign of safe oral
intake.
Neither method of artifical feeding is 100%
safe. Both carry a significant risk of aspiration still
occuring. This is presumably from feed refluxing and of
course normal salivation produces about 250-500mls of fluid a day which
can easily be aspirated also.
Treatments
of no proven
benefitNeither helpful
or harmful- Corticosteroids
in acute ischaemic stroke
- Anticoagulation as
secondary prevention unless AF
- Early treatment with
calcium antagonists
- Surgical decompression in
cerebral oedema
- Intravenous mannitol
Potentially
harmful- Intravenous heparin
- Intravenous
calcium antagonists